Royalty Report: Drugs, Cancer, Therapeutic – Collection: 363531

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Biotechnology
  • Drug Discovery
  • Diagnostic
  • Disease
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 363531

License Grant
Licensor granted the Turkish Licensee an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus.
License Property
Vicineum is a locally administered fusion protein developed for bladder cancer. Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety.
Field of Use
Field of use is for the treatment of BCG-unresponsive NMIBC, a non-muscle invasive bladder cancer.

IPSCIO Record ID: 313340

License Grant
The Licensor granted Chinese Licensee an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Licensor, to develop, manufacture and commercialize Vicineumâ„¢ (the Licensed Product) for the treatment of non-muscle invasive bladder cancer (NMIBC) and other types of cancer (the Field) in China, Hong Kong, Macau and Taiwan (the Territory). The Licensor also granted Licensee a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Licensor to develop, manufacture and commercialize the Licensed Product in the Territory. The Licensor retains development, manufacturing and commercialization rights with respect to Vicineum in the rest of the world.
License Property
Licensed Product means VicineumTM, also known as VB4-845, a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A. The Licensor has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with high-risk, bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) (the VISTA Trial).

Licensor is a late-stage clinical company developing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.

Field of Use
“Field” means the prevention and treatment of cancers, including; but not limited to, high-risk non-muscle invasive bladder cancer (“NMIBC”), and various sub-types of NMIBC.

IPSCIO Record ID: 304180

License Grant
Licensor grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products to the Licensee.
License Property
These patents cover some key aspects of Vicinium.  

Vicinium, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).

Field of Use
The agreement grants Licensee access to Licensor’s patent technology for certain antibody products to be used for the treatment of bladder cancer.

Licensee is a late-stage clinical company developing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 229530

License Grant
The Licensor of United Kingdom and Licensee into an exclusive license agreement granting an exclusive license, with the right to sublicense, under certain patents and technology relating to the de-immunization of Licensees cytotoxin Bouganin.  Licensee has the worldwide exclusive right, with the right to sublicense, under the licensed patents and technology to, among other things, make, have made, use or sell products incorporating deBouganin.
License Property
The de-immunized cytotoxin is known as deBouganin, and has been incorporated into Licensees product candidate, VB6-845d, relating to the treatment of cancer.
Field of Use
This agreement is for therapeutic and in vivo diagnostic purposes in humans.  Licensee is a biologics oncology company focused primarily on designing, engineering and developing targeted protein therapeutics, or TPTs, a single protein therapeutics composed of targeting moieties genetically fused via a peptide linker domain to cytotoxic protein payloads that are produced through proprietary recombinant one-step manufacturing process, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 27133

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, and to sell and have sold any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.  Upon written approval by PHS which will be given within thirty (30) days of a written request by Licensee, said approval not to be unreasonably withheld, Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
License Property
Patent(s) or Patent Application(s) that are Licensed Patent Rights
– U.S. Patent 5,614,191 issued March 25, 1997
– USSN 08/821,840 (div of 08/404,685) filed March 21, 1997
Patent(s) or Patent Application(s) that are Background Patent Rights
– U.S. Patent 4,892,827 issued January 9, 1990

The Company entered into an exclusive worldwide licensing agreement with the National Institutes of Health and the FDA to develop and commercialize an IL-13 chimeric protein therapy.

The IL-13 chimeric protein is the fusion of the receptor-binding ligand IL-13 with a derivative of Pseudomonas exotoxin (PE38QQR).  Research has demonstrated that some solid tumors express high numbers of IL-13 receptors on their cell surfaces.  These receptor sites become a specific target for the IL-13 chimeric protein for inducing cytotoxicity at nanogram concentrations.  IL-13 Chimeric Protein Exotoxin is a genetically engineered compound incorporating a highly toxic material that destroys cells once linked to the target receptor on its surface.  Pre-clinical trials ongoing, initiate Phase I in the 2nd Quarter, 1999.

Cancer Indication Renal Cell, Brain, Kaposi's Sarcoma, Breast.

Field of Use
Licensed Fields of Use To use of the chimeric molecule hIL-13-PE38QQR or cphIL-13-PE38QQR to treat cancer.

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.